Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Epidemiol Infect ; 149: e230, 2021 10 22.
Article in English | MEDLINE | ID: mdl-34674789

ABSTRACT

We conducted a retrospective observational study in patients with laboratory-confirmed coronavirus disease (COVID-19) who received medical care in 688 COVID-19 ambulatory units and hospitals in Mexico City between 24 February 2020 and 24 December 2020, to study if the elderly seek medical care later than younger patients and their severity of symptoms at initial medical evaluation. Patients were categorised into eight groups (<20, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79 and ≥80 years). Symptoms at initial evaluation were classified according to a previously validated classification into respiratory and non-respiratory symptoms. Comparisons between time from symptom onset to medical care for every age category were performed through variance analyses. Logistic regression models were applied to determine the risk of presenting symptoms of severity according to age, and mortality risk according to delays in medical care. In total, 286 020 patients were included (mean age: 42.8, s.d.: 16.8 years; 50.4% were women). Mean time from symptom onset to medical care was 4.04 (s.d.: 3.6) days and increased with older age categories (P < 0.0001). Mortality risk increased by 6.4% for each day of delay in medical care from symptom onset. The risk of presenting with the symptoms of severity was greater with increasing age categories. In conclusion, COVID-19 patients with increasing ages tend to seek medical care later, with higher rates of symptoms of severity at initial presentation in both ambulatory units and hospitals.


Subject(s)
Aging , COVID-19/epidemiology , Time-to-Treatment/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/diagnosis , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Mexico/epidemiology , Middle Aged , Patient Acceptance of Health Care/statistics & numerical data , Retrospective Studies , SARS-CoV-2 , Severity of Illness Index , Young Adult
2.
Parasite Immunol ; 41(3): e12540, 2019 03.
Article in English | MEDLINE | ID: mdl-29888463

ABSTRACT

Congenital transmission of leishmaniasis is recognized in cases detected by passive surveillance. Most cases are from low-resource countries, limiting the study of several important aspects of this route of infection, including the offspring's immune response. Studies on natural and experimentally infected animals suggest that parasites might be transmitted to the embryo or foetus at any time during pregnancy. As immune system undergoes sequential stages of development, an infection before the time of self-recognition could lead to central tolerance, making an individual specifically tolerant and susceptible to infection. In the alternative scenario, infection after self-recognition would allow the proper development of T-lymphocyte clones in response to Leishmania antigens, providing resistance to the disease. Newborns undergo a transient period of low expression of several immune surface molecules and a naïve adaptive immune response with no memory, which together might contribute to slow elimination of the parasite over several months. This insight is a proposed independent mechanism of the previously proven T-cell exhaustion and must be investigated. Analyses of infected placenta, cord blood and infant immunity are required for a better understanding of immunity in congenital leishmaniasis infection.


Subject(s)
Immune Tolerance/immunology , Infectious Disease Transmission, Vertical , Leishmania/immunology , Leishmaniasis/immunology , T-Lymphocytes/immunology , Female , Fetal Blood/parasitology , Humans , Infant, Newborn , Placenta/parasitology , Pregnancy
3.
World J Microbiol Biotechnol ; 34(3): 38, 2018 Feb 19.
Article in English | MEDLINE | ID: mdl-29460068

ABSTRACT

We evaluated, for the first time, the leishmanicidal potential of decanethiol functionalized silver nanoparticles (AgNps-SCH) on promastigotes and amastigotes of different strains and species of Leishmania: L. mexicana and L. major isolated from different patients suffering from localized cutaneous leishmaniasis (CL) and L. mexicana isolated from a patient suffering from diffuse cutaneous leishmaniasis (DCL). We recorded the kinetics of promastigote growth by daily parasite counting for 5 days, promastigote mobility, parasite reproduction by CFSE staining's protocol and promastigote killing using the propidium iodide assay. We also recorded IC50's of promastigotes and amastigotes, therapeutic index, and cytotoxicity by co-culturing macrophages with AgNps-SCH or sodium stibogluconate (Sb) used as reference drug. We used Sb as a reference drug since it is used as the first line treatment for all different types of leishmaniasis. At concentrations 10,000 times lower than those used with Sb, AgNps-SCH had a remarkable leishmanicidal effect in all tested strains of parasites and there was no toxicity to J774A.1 macrophages since > 85% were viable at the concentrations used. Therapeutic index was about 20,000 fold greater than the corresponding one for Sb treated cells. AgNps-SCH inhibited > 80% promastigote proliferation in all tested parasites. These results demonstrate there is a high leishmanicidal potential of AgNps-SCH at concentrations of 0.04 µM. Although more studies are needed, including in vivo testing of AgNps-SCH against different types of leishmaniasis, they can be considered a potential new treatment alternative.


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania/drug effects , Metal Nanoparticles/chemistry , Silver/pharmacology , Animals , Antimony Sodium Gluconate/pharmacology , Antiprotozoal Agents/administration & dosage , Cell Proliferation/drug effects , Humans , Inhibitory Concentration 50 , Kinetics , Leishmania/growth & development , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/parasitology , Macrophages/drug effects , Macrophages/parasitology , Mice , Mice, Inbred BALB C , Silver/administration & dosage
4.
Behav Brain Res ; 321: 137-147, 2017 03 15.
Article in English | MEDLINE | ID: mdl-28062256

ABSTRACT

Aging increases the vulnerability to stress and risk of developing depression. These changes have been related to a reduction of dehydroepiandrosterone (DHEA) levels, an adrenal steroid with anti-stress effects. Also, adult hippocampal neurogenesis decreases during aging and its alteration or impaired is related to the development of depression. Besides, it has been hypothesized that DHEA increases the formation of new neurons. However, it is unknown whether treatment with DHEA in aging may stimulate the dendrite maturation of newborn neurons and reversing depressive-like signs evoked by chronic stress exposure. Here aged male rats (14 months old) were subjected to a scheme of chronic mild stress (CMS) during six weeks, received a treatment with DHEA from the third week of CMS. Changes in body weight and sucrose preference (SP) were measured once a week. DHEA levels were measured in serum, identification of doublecortin-(DCX)-, BrdU- and BrdU/NeuN-labeled cells was done in the dentate gyrus of the hippocampus. CMS produced a gradual reduction in the body weight, but no changes in the SP were observed. Treatment enhanced levels of DHEA, but lack of recovery on body weight of stressed rats. Aging reduced the number of DCX-, BrdU- and BrdU/NeuN- cells but DHEA just significantly increased the number of DCX-cells in rats under CMS and controls, reaching levels of young non-stressed rats (used here as a reference of an optimal status of health). In rats under CMS, DHEA facilitated dendritic maturation of immature new neurons. Our results reveal that DHEA improves neural plasticity even in conditions of CMS in middle age rats. Thus, this hormone reverted the decrement of DCX-cells caused during normal aging.


Subject(s)
Aging/drug effects , Dehydroepiandrosterone/pharmacology , Dendrites/drug effects , Dentate Gyrus/drug effects , Psychotropic Drugs/pharmacology , Stress, Psychological/drug therapy , Aging/physiology , Aging/psychology , Animals , Antigens, Nuclear/metabolism , Body Weight/drug effects , Bromodeoxyuridine , Cell Survival/drug effects , Cell Survival/physiology , Chronic Disease , Dehydroepiandrosterone/blood , Dendrites/metabolism , Dendrites/pathology , Dentate Gyrus/metabolism , Dentate Gyrus/pathology , Dietary Sucrose , Doublecortin Domain Proteins , Doublecortin Protein , Male , Microtubule-Associated Proteins/metabolism , Nerve Tissue Proteins/metabolism , Neurogenesis/drug effects , Neurogenesis/physiology , Neuropeptides/metabolism , Psychotropic Drugs/blood , Random Allocation , Rats, Wistar , Stress, Psychological/metabolism , Stress, Psychological/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...